A Phase IB Study of Crizotinib (XALKORI) and Sunitinib (SUTENT) in Metastatic Breast Cancer

Next Previous
Trial Profile

A Phase IB Study of Crizotinib (XALKORI) and Sunitinib (SUTENT) in Metastatic Breast Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Crizotinib (Primary) ; Sunitinib (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms CRIZENT

    • Most Recent Events

    • 08 Aug 2017 Status changed from recruiting to discontinued due to poor accrual.
    • 23 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Aug 2018.
    • 23 Aug 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top